Nadia's Feed
Feb 14, 2015

Exclusive: Informatica seeks advisers to revive sale process – sources

By Nadia Damouni, Liana B. Baker and Greg Roumeliotis

(Reuters) – Enterprise software maker Informatica Corp (INFA.O: Quote, Profile, Research, Stock Buzz) is looking to hire new financial advisers that will help it revive a sale process and defend itself from activist hedge fund Elliott Management Corp, according to people familiar with the matter.

An auction for Informatica run by investment banking boutique Qatalyst Partners LP was put on hold early last month after interest received from private equity firms, including a consortium led by Hellman & Friedman LLC, failed to lead to a deal, the people said this week.

Feb 7, 2015

Exclusive: Top Fox investors seek to convert voting shares, Murdoch may benefit

NEW YORK (Reuters) – Several top investors in Twenty-First Century Fox Inc are pressing for the right to swap their voting shares for ordinary shares, which are trading at an unusual premium, even though the move could hand even more control of the company to Rupert Murdoch, according to people familiar with the matter.

Fox’s dual-class share structure already gives the 83-year-old media mogul control over 39.7 percent of voting rights, even though he and his family hold only a 12 percent equity stake.

Feb 6, 2015

Exclusive: Top Fox investors seek to convert voting shares, Murdoch may benefit – sources

NEW YORK (Reuters) – Several top investors in Twenty-First Century Fox Inc are pressing for the right to swap their voting shares for ordinary shares, which are trading at an unusual premium, even though the move could hand even more control of the company to Rupert Murdoch, according to people familiar with the matter.

Fox’s dual-class share structure already gives the 83-year-old media mogul control over 39.7 percent of voting rights, even though he and his family hold only a 12 percent equity stake.

Feb 3, 2015

How the Actavis deal upended Allergan No. 2′s CEO ambitions

NEW YORK, Feb 3 (Reuters) – For two decades, Allergan Inc
president Doug Ingram labored to transform the
Botox-maker from a sleepy eye care upstart to a global
aesthetics giant. He was just a few months away from getting the
top job when a merger deal with Actavis Plc in November
thwarted his ambitions.

Ingram has now accepted an advisory role to facilitate the
merger and will soon be looking for a job outside the combined
company. Allergan’s derailed succession plans, disclosed by
Ingram and other top executives in interviews with Reuters,
underscore how corporate mergers can leave even some of the
industry’s top executives in the cold.

Jan 23, 2015

Who’s afraid of China’s economy slowing? Not Alibaba’s Jack Ma

DAVOS, Switzerland (Reuters) – Jack Ma, executive chairman of Chinese e-commerce giant Alibaba Group Holding, isn’t worried about slowing Chinese economic growth, he told a meeting of business and political leaders in Davos, Switzerland.

“If China still keeps 9 percent growth of the economy there must be something wrong. You will never see the blue sky. You will never see quality. China should pay attention to the quality of the economy,” he said in a question-and-answer session at the World Economic Forum.

Jan 12, 2015

Insight – Ellison’s backing helps Kurian’s star to rise at Oracle

NEW YORK (Reuters) – Every Tuesday and Wednesday at around 2 pm, Larry Ellison, the founder of Oracle Corp, gathers his lieutenants in the board room on the top floor of the software giant’s headquarters in Redwood City, California to hear engineers present new products and strategies.

Several people who have attended the meetings over the years said all the top Oracle executives have assigned seats – including Ellison himself, the two co-CEOs Safra Catz and Mark Hurd, and Thomas Kurian, who was appointed president of software development last week.

Jan 12, 2015

Ellison’s backing helps Kurian’s star to rise at Oracle

NEW YORK, Jan 12 (Reuters) – Every Tuesday and Wednesday at
around 2 pm, Larry Ellison, the founder of Oracle Corp, gathers
his lieutenants in the board room on the top floor of the
software giant’s headquarters in Redwood City, California to
hear engineers present new products and strategies.

Several people who have attended the meetings over the years
said all the top Oracle executives have assigned seats -
including Ellison himself, the two co-CEOs Safra Catz and Mark
Hurd, and Thomas Kurian, who was appointed president of software
development last week.

Dec 17, 2014

American Apparel names new CEO, officially ousts founder

By Jeffrey Dastin and Nadia Damouni

(Reuters) – American Apparel Inc has fired its Chief Executive Officer Dov Charney six months after suspending him, ending a tenure racked with sexual assault allegations and scandal.

The retailer, known for its provocative clothing ads, also announced Tuesday that Paula Schneider will take over as chief executive on Jan. 5. Schneider currently serves as president of ESP Group Ltd, which owns brands such as English Laundry.

Dec 9, 2014

Exclusive: Valeant to drop deal-making in near term to cut debt, boost stock

NEW YORK/WINNIPEG (Reuters) – Valeant Pharmaceuticals International Inc (VRX.TO: Quote, Profile, Research, Stock Buzz) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

After spending $19 billion on 40 acquisitions since 2008, the Canadian drugmaker is regrouping after failing last month to acquire Botox-maker Allergan Inc (AGN.N: Quote, Profile, Research, Stock Buzz), they said.

Dec 9, 2014

Valeant to drop deal-making in near term to cut debt, boost stock

NEW YORK/WINNIPEG, Dec 9 (Reuters) – Valeant Pharmaceuticals
International Inc is abandoning its
growth-by-acquisitions strategy for the time being to try to
reduce debt, boost its stock price and one day return to its
traditional deal-making in a stronger position, people familiar
with the matter told Reuters.

After spending $19 billion on 40 acquisitions since 2008,
the Canadian drugmaker is regrouping after failing last month to
acquire Botox-maker Allergan Inc, they said.